Novo Nordisk A/S (NYSE:NVO) Stock Price Up 0.8%

Novo Nordisk A/S (NYSE:NVO)’s stock price traded up 0.8% during trading on Monday . The stock traded as high as $126.05 and last traded at $125.47. 1,071,248 shares were traded during mid-day trading, a decline of 78% from the average session volume of 4,933,323 shares. The stock had previously closed at $124.51.

Analysts Set New Price Targets

Several analysts have recently issued reports on NVO shares. BMO Capital Markets began coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, April 1st. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. Finally, UBS Group started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Trading Down 0.4 %

The business has a 50-day moving average of $126.16 and a 200-day moving average of $110.32. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The stock has a market capitalization of $553.99 billion, a price-to-earnings ratio of 45.64, a PEG ratio of 2.06 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. As a group, research analysts forecast that Novo Nordisk A/S will post 3.33 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were paid a dividend of $0.664 per share. This represents a dividend yield of 0.9%. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio is 49.17%.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of large investors have recently modified their holdings of NVO. Cornerstone Planning Group LLC acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth approximately $29,000. First PREMIER Bank acquired a new stake in Novo Nordisk A/S during the 1st quarter valued at $25,000. Tower Research Capital LLC TRC grew its holdings in Novo Nordisk A/S by 165.3% during the 1st quarter. Tower Research Capital LLC TRC now owns 199 shares of the company’s stock valued at $32,000 after buying an additional 124 shares during the last quarter. CNB Bank acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $26,000. Finally, Pacific Center for Financial Services grew its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.